Advancing Ovarian Cancer Treatment: Insights From Emerging Therapies

Bradley J. Monk, MD, FACS, FACOG, discusses how comprehensive molecular testing in ovarian cancer has evolved to include BRCA, folate receptor alpha, and emerging biomarkers like HER2 and CCNE1 while addressing challenges in education, reimbursement, and tumor heterogeneity that impact widespread adoption.